Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

Eli Lilly also forecast annual profit largely ... The company said it expects U.S. growth of its diabetes and weight-loss drugs to be consistent with 2024. Lilly and Novo have spent billions ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Diabetes and Obesity Drugs Fuel Eli Lilly Profit in the Final Quarter of 2024 Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments ...